Madhavan Balachandran - Amgen Executive VP of Operations

AMGN34 Stock  BRL 49.70  0.75  1.53%   

EVP

Mr. Madhavan Balachandran is the Executive Vice President Operations of Amgen Inc since 2012.
Age 64
Tenure 12 years
Phone805 447 1000
Webhttps://www.amgen.com
Balachandran joined the Company in 1997 and has held leadership positions in engineering, information systems and operations. From October 2007 to August 2012, Mr. Balachandran was Senior Vice President, Manufacturing. From February 2007 to October 2007, Mr. Balachandran was Vice President, Site Operations. From May 2002 to February 2007, Mr. Balachandran was Vice President, Puerto Rico Operations. Prior to 2002, Mr. Balachandran served as Associate Director Capital Projects before his promotion to Director Engineering and then to Vice President, Information Management. Previously, Mr. Balachandran served as Vice President, Engineering at Burroughs Wellcome & Company.

Amgen Management Efficiency

The company has return on total asset (ROA) of 0.0997 % which means that it generated a profit of $0.0997 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 1.2647 %, meaning that it generated $1.2647 on every $100 dollars invested by stockholders. Amgen's management efficiency ratios could be used to measure how well Amgen manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 37.35 B in total debt. Amgen Inc has a current ratio of 1.5, which is within standard range for the sector. Debt can assist Amgen until it has trouble settling it off, either with new capital or with free cash flow. So, Amgen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amgen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amgen to invest in growth at high rates of return. When we think about Amgen's use of debt, we should always consider it together with cash and equity.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. AMGEN DRN operates under Drug ManufacturersGeneral classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 24200 people. Amgen Inc (AMGN34) is traded on Sao Paulo Exchange in Brazil and employs 25,200 people.

Management Performance

Amgen Inc Leadership Team

Elected by the shareholders, the Amgen's board of directors comprises two types of representatives: Amgen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amgen. The board's role is to monitor Amgen's management team and ensure that shareholders' interests are well served. Amgen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amgen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Linda Louie, Vice President - Finance, Chief Accounting Officer
Frank Herringer, Independent Director
Nancy Grygiel, Sr Officer
Francois Carbonnel, Independent Director
Rebecca Henderson, Independent Director
Annette Such, Chief Accounting Officer
Sanders Williams, Independent Director
Vance Coffman, Lead Independent Director
David Reese, Executive Vice President - Research and Development
Tyler Jacks, Independent Director
Brian McNamee, Executive Vice President - Full Potential Initiatives
Gregory Garland, Independent Director
Charles Holley, Independent Director
Esteban Santos, Executive Vice President Operations
Jonathan Graham, Senior Vice President General Counsel, Secretary
Sean Harper, Executive Vice President - Research and Development
Mike Zahigian, VP Officer
Ellen Kullman, Independent Director
Frank Biondi, Independent Director
Arvind Sood, IR Contact Officer
David Meline, Executive Vice President, Chief Financial Officer
Ronald Sugar, Independent Director
Stuart Tross, Senior Vice President - Human Resources
Robert Bradway, Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee
Murdo Gordon, Executive Vice President of Global Commercial Operations
Peter Griffith, Chief Financial Officer, Executive Vice President
Wanda Austin, Independent Director
Robert Eckert, Lead Independent Director
Madhavan Balachandran, Executive VP of Operations
Lori Johnston, Senior Vice President - Human Resources
Brian Druker, Independent Director
Cynthia Patton, Senior Vice President Chief Compliance Officer
Greg Garland, Independent Director
Robert Williams, Independent Director
Amy Miles, Independent Director
Judith Pelham, Independent Director
David Baltimore, Independent Director
Fred Hassan, Independent Director
David Piacquad, Senior Vice President - Business Development
Anthony Hooper, Executive VP of Global Commercial Operations
David MD, Ex RD

Amgen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amgen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Amgen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Amgen's short interest history, or implied volatility extrapolated from Amgen options trading.

Pair Trading with Amgen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.

Moving together with Amgen Stock

  0.7N1VS34 Novartis AGPairCorr

Moving against Amgen Stock

  0.85WEGE3 WEG SAPairCorr
  0.84TMCO34 Toyota MotorPairCorr
  0.82BBAS3 Banco do Brasil SplitPairCorr
  0.81TSMC34 Taiwan SemiconductorPairCorr
  0.79LILY34 Eli LillyPairCorr
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the Amgen Inc information on this page should be used as a complementary analysis to other Amgen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for Amgen Stock analysis

When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Transaction History
View history of all your transactions and understand their impact on performance
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.